

# Prevalence and antibiotic resistance of *Streptococcus pneumoniae* among different hospitals in Saudi Arabia

Ayman Khalid Johargy<sup>1</sup>, Adil Jamal<sup>\*,2</sup>, Aiman Mohammed Mumenah<sup>1</sup>

<sup>1</sup> Department of Medical Microbiology, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia

<sup>2</sup> \*Molecular Biology, Department of Nursing Sciences and Research, College of Nursing, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia

## ABSTRACT

**Objective:** Present Study was directed to examine the pervasiveness, antibiotics resistance and susceptibility array in *Streptococcus pneumoniae* gram positive and gram negative isolated strains.

**Methodology:** In current study, 6549 suspected samples were proceeded to confirm pneumonia positive cases obtained from various hospitals. Gram positive and gram negative strains were isolated and characterized by conventional biochemical techniques. Antibiotic susceptibility test was carried out using the disk diffusion test according to the Clinical and Standard Laboratory Institute guidelines (CLSI). Further, streptococcus based isolates were investigated using MacConkey agar.

**Results:** A total number of 6549 suspected clinically samples were collected and 3716 (56.7%) pneumonia cases were confirmed to be positive. More than half of the confirmed cases fall in the age of 20-65 years and male proportion was found to be 64%. Interestingly, 98.2% of the cases were hospital acquired pneumoniae (HAP). *P. aeruginosa* most widely recognized isolate both hospital and community acquired (CA) etiological agent contributed 18.4% and 32.2% proportion respectively.

**Conclusion:** Clinicians ought to know that average observational pneumonia treatment administrations may not function admirably because of the diverse microbes. This requires sputum examining before beginning treatment for recognizable proof and affectability testing subsequent to a solitary measurement of antimicrobial treatment preceding pneumonia finding might impede the discovery of the causative specialists.

**Keywords:** *Streptococcus pneumoniae*, prevalence, antibiotic, resistance, Saudi Arabia

## 1. INTRODUCTION

*Streptococcus pneumoniae* is a key respiratory pathogen that is actively involved in couple of respiratory sickness including otitis media, pneumonia and sinusitis [1]. The prevalence of pneumococcal nasal pharyngeal asymptomatic colonization in the adults has been increased [2]. The biological corner for *S. pneumoniae* is the human nasopharynx. Transfer of pneumococci in the nasopharynx is more common in adults than young ones. The span of carriage is affected by host and pathogen-related components. The growing recurrence of hostile to microbial safe *S. pneumoniae* strains raises another risk to the treatment of disease [3]. In the mid of recent decade, antimicrobial resistance has expanded around the world [4]. Specifically, imperviousness to penicillin and the macrolides has spread rapidly among withdraws of *S. pneumoniae* [5].

Few studies have proposed a connection between pneumococcal macrolide resistance and treatment disappointment in patients with group *cause* respiratory tract infections (RTI) [6]. The development of Multi Drug Resistance safe *S. pneumoniae* (MDRSP) has been seen in different nations over the past decades. The developing resistance of *S. pneumoniae* to usually utilized antimicrobials underlines the critical requirement for immunizations to be utilized to control pneumococcal disease.

Current study focuses to determine any possible measurable relationship between the frequency of pneumonia cases and different patients demographic information including; age, sex, source of infection (i.e., community acquired pneumonia (CAP's) or Hospital acquired pneumonia (HAP's)). Present study also aims to direct the resistance rate among both Gram-positive and Gram-negative clinical disengages from pneumonia cases including *S. pneumonia* among various hospitals of Saudi Arabia. Finally, aim of the present study is to decide the circulation of pneumonia cases among various hospitals, to examine prevalence of pneumonia cases in Hajj and Umrah seasons.

## 2. MATERIALS AND METHODS

### 2.1 Samples collection

The study was conducted using clinical microbiology data collected at four different acute care hospitals during period of 1<sup>st</sup> Jumada al-Thani to the 30<sup>th</sup> Jumada al-Awwal of the Islamic year 1429-1430 AH (6 Jun 2008 - 25 May 2009). The study was ethically approved by the institutional review board at each of the four participating hospital prior to study commencement. Informed consent was obtained from patients or their guardians those included in sampling of this study.

### 2.2 Sampling criteria

The criteria for the enrollment was all those patients with clinical diagnosis of pneumonia including; coughing with sputum, cold with shivering, fever, chest pain, shortness of breath and rapid breathing. The sputum samples submitted to the microbiology laboratory. Four hundred and forty two sputum were obtained from Al-Noor, King Faisal, King Abdul Aziz and Hera hospitals.

### 2.3 Sub culture and storage of specimens

The organisms were sub-cultured on blood and MacConkey agar. After overnight incubation at 37°C, they were isolated in trypticase soya broth, containing 15% Glycerol (850 µl bacterial broth and 150 µl glycerol), further stored at -80 °C.

### 2.4 Automated identification and antimicrobial susceptibility testing (AST)

The study was conducted using clinical microbiology data collected at four different acute care hospitals. For the purposes of this study and consistent with Clinical and Laboratory Standards Institute (CLSI) guidelines for antimicrobial susceptibility reports, only the first organism-specific clinical culture per patient, per year, was included [7]. The method for determining susceptibility to specific antimicrobial agents varied slightly between isolates and between the four institutions, but always conformed to established national standards for laboratory practice. Laboratory methods did not vary at any hospital during the period in which data were collected for the study. In some cases, the range of pathogens or antimicrobial agents that was tested was limited for practical reasons unrelated to the conduct of the study. Bacterial isolates for which antimicrobial susceptibility results were not available for a particular agent were excluded only from the analysis of that specific agent, but remained eligible for inclusion in the analysis of other agents for which susceptibility data were available.

Preserved bacteria were sub cultured in a suitable media and incubated accordingly to obtain a pure culture. Around 3 ml of clean saline (fluid 0.45% NaCl, pH 7.0) was put into a reasonable plastic test tube. By then adequate number of morphologically comparative states of immaculate microbes was exchanged to a tube containing the saline to make homogenous suspension with an identical thickness of McFarland (No.0.50-0.63) using calibrated VITEK2 Densi Chek 2 system (bioMérieux, Durham, NC) [8]. The tube was then

set in the tape with the recognizable proof card and information passage. To another tube holding 3 ml of saline, 280 ml of the suspension prepared for Antimicrobial susceptibility testing (AST)-GP was then transferred. The tube was then put in the anti-infection agents weakness tape, the recognizable proof GP depends on 43 biochemical tests measured carbon source usage, enzymatic actions and resistance. For the MIC (minimum inhibitory concentration) technique, AST (Antimicrobial susceptibility testing) card contains 64 micro wells were used. While control well was occupant on all card with the remaining wells containing premeasured measures of particular antimicrobials consolidated with culture medium. MIC values were determined for each antimicrobial contained on the card after a defined period of time (about 18 hrs).

## 2.5 Data Analysis

Data entry and statistical analysis were performed using the Statistical Package for Social Sciences (SPSS program Ver 17.0). Descriptive statistics and Fisher's test were performed. Statistical significance was set at <0.05 to check the level of significance.

## 3. RESULTS

Data expressed 56%, 18%, 15% and 11% samples collected from Al-Noor hospital (ANH), King Faisal hospital (KFH), King Abdul Aziz hospital (KAH) and Hera hospital respectively. Current data showed that out of 6549 samples, 3716 samples were positive representing a proportion of 56.7% (data not shown). The difference between the total samples tested and positive samples was calculated statistically significant (p. value <0.05).

Data collected during one year expressed significant number of pneumonia cases (519, 14% of total positive) in Dull Hijjah followed by Shawwal month (389, 10.5%) (data not shown). Gender and age groups results demonstrated that the infection affects all age groups. Significant number of both suspected and positive cases were reported in the age groups of 20-65 years, followed by elderly (>65 years) people representing proportion of 51% and 36% respectively. Significantly higher ratio of pneumonia cases was observed in male gender as compared to females.

In current study, total 1,733 (98.2%) indoor while 31 (1.8%) outdoor patients were found affected to pneumonia. Results displayed that most indoor-patients infected with pneumonia were related to ICU (49.6%) ward, followed by medical wards (MW) (31.7%), surgical wards (SW) (10.6%). Out-door patients department (OPD) and emergency room (ER) contributed 64.5% and 35.5% respectively.

The study disclosed that the majority of pneumonia were HAP cases (98.2%), typically caused by *P. aeruginosa* (18.4%), *A. baumannii* (14.4%) and *S. aureus* (12.5%) followed by *K. pneumoniae* (11.5%). Among the isolates causing CAP (total of 1.8%), *P. aeruginosa* (32.2%) contributed maximum followed by *K. pneumoniae* (29%) and *S. aureus* (12.9%) (Figure 3.1). In case of gram-positive isolates higher antimicrobial sensitivity was reported for *S. aureus* followed by *S. pneumoniae* (Figure 3.3; Table 3.1). Among gram negative isolates significantly higher antimicrobials sensitivity was reported in case of *P. aeruginosa*, *K. pneumoniae* and *A. baumannii* (Figure 3.3; Table 3.2).

## 4. DISCUSSION

Pneumonia is distraction of the lungs, including the alveolar ducts and sacs, in relationship with radiographic signs [9]. Pneumonia positions sixth among the reasons for death today [10]. Clinically, there are various types of pneumonia; however a typical method for separating it is to arrange it as CAP and HAP. The merge of physical events, stuffing and any prior health conditions upgrade the exposure of getting potent illness accompanied by Hajj [11]. Because of its simplicity of transmission by RTI quicken the most widely recognized contagious infection during Hajj and Umrah seasons [12]. RTI was accounted for as the most widely recognized cause (57%) with pneumonia being the main purpose behind affirmation in 39.4% of all patients in Dull Hijjah and Umrah season [13]. Pneumonia has been most widely recognized reasons for hospitalization during Hajj, accounting 19.7% [14]. Most surprisingly higher number of pneumonia cases in Dull Hijjah month reported followed by Umrah (Ramdan) surely in light of the fact that more number of explorers originating from

everywhere throughout the world because of significant chest infections, fatigue and poor nutrition among pioneers [11].

Among the four hospitals incorporated into this study, results demonstrated that ANH had more than half of aggregate sputum tests submitted for testing. Present finding is most likely because of two components: the first is the higher number of beds in ANH in contrast with different hospitals, and another reason might be the physical closeness of ANH to Mena, Arafat and Muzdalifa. Positive samples (56.7%) with a momentous gap between the aggregate specimens tried were highlighted at cutoff P-value <0.05. This vast gap could be because of a few variables including clinical misdiagnosis of cases, antimicrobial use, lacking method of sputum sampling and infrequent pneumonia microbes that are not routinely investigated.

In the present study, the occurrence of pneumonia in male was higher than in females (1.8:1) potentially on account of the distinctions in the societal position between the two genders. Current finding follows with those already reported in countries like Iraq, USA, Thailand and Saudi Arabia [15-17]. A comparative finding was seen during month of Dull Hijjah, where the proportion of disease in the middle of male and female was 1.6:1. Present study shows 98.2% indoor-patients and 1.8% outdoor patients which is in contrast to previous studies, both at neighborhood [12] and global levels [16-17]. In current study, greater part of HAP cases were mainly contributed by *P. aeruginosa* (18.4%) and *A. baumannii* (14.4%) followed by *S. aureus* (12.5%) and *K. pneumoniae* (11.5%). Current results follow similar studies done national and global level which also reported that most HAP cases brought about by Gram-negative microorganisms [18-19].

In present study *P. aeruginosa* (32.2%), *K. pneumoniae* (29%) and *S. aureus* (12.9%) were observed to be most basic causative operators for pneumoniae among different hospital wards. Current findings are also supported by previous studies which also reported that *S. pneumoniae* is the most frequent microorganism for CAP [19-20]. This may be due to mishandling of observational treatment given to out-patients before taking sputum tests for microbiological refined. *S. aureus* (17.1%), *A. baumannii* (15.5%), *K. pneumonia* (14.5%) and *P. aeruginosa* (12.8%) are basic microbes found in Dull-Hajj season. The conclusion of pneumonia was confirmed in 72% patients. *M. tuberculosis* (28%) and Gram-negative (26%) were among the most widely recognized isolates. *S. pneumoniae* was distinguished in 10% patients while infrequent isolates were recognized in 6% patients. Past studies reported that the etiological operators of pneumonia in Hajj differed from those of CAP [11]. Most persistent pathogens causing *S. pneumoniae* were probably due to *H. influenza*, *K. pneumoniae*, and *S. pneumoniae* [21].

Most isolates in this study are multidrug resistant. This may be attributed to probability of the occurrence of genes that code for multiple antibiotics resistance in the isolates. Some of the ways by which bacteria can develop antibiotics resistance include: (i) Antibiotic inactivation – direct inactivation of the active antibiotic molecule [22]; (ii) Target modification – alteration of the sensitivity to the antibiotic by modification of the target [23]; (iii) Efflux pumps and outer membrane (OM) permeability changes–reduction of the concentration of drug without modification of the compound itself [24]; or (iv) Target bypass – some bacteria become refractory to specific antibiotics by bypassing the inactivation of a given enzyme. Resistance could be developed to antibiotics by variation in medication target proteins and adaptations that limit the absorption of the drug to the target [25].

## CONCLUSION

This study provides information on the most common pneumonia causes, and the demographic distribution of the disease. Our study outcomes will aid health care planners, administrators, and officials in order to provide optimal health care services to locals in general and pilgrims during Hajj and Umrah seasons. Clinicians should be aware that typical pneumonia treatment regimes may not work well due to the wide variety of isolated organisms. This necessitates taking a sputum sample before starting treatment for

201 identification and sensitivity testing since a single dose of antibiotic treatment prior to  
202 pneumonia diagnosis may hinder the detection of the causative agent.

203 **Acknowledgement**

204 This study was supported by the Medical Research Center, Institute of the Scientific  
205 Research and Islamic Heritage Revival, Umm Al-Qura University, Makkah, Kingdom of  
206 Saudi Arabia.

207 **AUTHORS CONTRIBUTION:** Ayman Khalid Johargy planned, designed, approved study  
208 concept and supervised in collection, assembly, possession of raw data, funds arrangement  
209 and valuable suggestions in article preparation. Adil Jamal performed data analysis, critical  
210 discussion and manuscript preparation. Aiman Mohammed Momenah carried out sampling,  
211 administrative, technical and material support to accomplish this study.

212 **COMPETING INTERESTS:** Authors have declared that no competing interests exist.

## 213 REFERENCES

- 214 1. del Campo R, Morosini M I, de la Pedrosa E G, Fenoll A, Munoz-Almagro C, Maiz L.  
215 Population structure, antimicrobial resistance and mutation frequencies of *Streptococcus*  
216 *pneumoniae* isolates from cystic fibrosis patients. J Clin Microbiol 2005. 43(5):2207-14.
- 217 2. Maeda Y, Elborn J S, Parkins M D, Reihill J, Goldsmith C E, Coulter WA. Population  
218 structure and characterization of viridans group streptococci (VGS) including  
219 *Streptococcus pneumoniae* isolated from adult patients with cystic fibrosis (CF). J Cyst  
220 Fibros 2011. 10(2):133-9.
- 221 3. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal  
222 disease in adults. Clin. Microbiol. Infect 2012. 18:7-14.
- 223 4. Marchese A, Gualco L, Cochetti I, Montanari M P, Speciale A M, Musumeci S R, Varaldo  
224 P E, Nicoletti G, Schito G C. Antibiotic susceptibility and serotype distribution in  
225 *Streptococcus pneumoniae* circulating in Italy: results of the SEMPRES surveillance study  
226 (2000-2002). Int J Antimicrob Agents 2005. 26:138-145.
- 227 5. Klugman KP, Lonks J R. Hidden epidemic of macrolide-resistant pneumococci. Emerg  
228 Infect Dis 2005. 11:802-807.
- 229 6. Rzeszutek M, Wierzbowski A, Hoban D J, Conly J, Bishai W, Zhanel G G. A review of  
230 clinical failures associated with macrolide resistant *Streptococcus pneumoniae*. Int J  
231 Antimicrob Agents 2004. 24:95-104.
- 232 7. Clinical and Laboratory Standards Institute (CLSI). Performance standards for  
233 antimicrobial susceptibility testing; fifteenth informational supplement. CLSI/NCCLS  
234 document M100–S15. 2005. CLSI, Wayne, PA.
- 235 8. Nimalie D, Stone, Caroline M. O'Hara, Portia P. Williams, John E. McGowan, Jr. Fred C.  
236 Tenover. Comparison of Disk Diffusion, VITEK 2, and Broth Microdilution Antimicrobial  
237 Susceptibility Test Results for Unusual Species of *Enterobacteriaceae*. Journal of  
238 Clinical Microbiology 2007, p. 340-346
- 239 9. Durrington H J, Summers C. Recent changes in the management of community acquired  
240 pneumonia in adults. BMJ 2008.336:1429-1433.
- 241 10. Memish Z, Shibl A, Ahmed Q. Guidelines for the management of community-acquired  
242 pneumonia in Saudi Arabia: a model for the Middle East region. Int J Antimicrob Agents  
243 2002. 20 (Suppl 1): S1-12
- 244 11. Alzeer A H. Respiratory tract infection during Hajj. Ann.Thorac.Med 2009. 4(2):50-53.
- 245 12. Ahmed Q A, Arabi Y M, Memish Z A. Health risks at the Hajj. Lancet 2006. 367:1008-  
246 1015.
- 247 13. Al-Ghamdi S M, Akbar H O, Qari YA, Fathaldin O A, Al-Rashed R S. Pattern of  
248 admission to hospitals during muslim pilgrimage (Hajj). Saudi. Med. J 2003. 24:1073-  
249 1076.
- 250 14. Madani T A, Ghabrah T M, Al-Hedaithy M A, Alhazmi M A, Alazraqi T A, Albarrak A M,  
251 Ishaq A H. Causes of hospitalization of pilgrims in the Hajj season of the Islamic year  
252 1423 (2003). Ann.Saudi.Med 2006. 26: 346-351.
- 253 15. Puthavathana P, Habanananda S, Wasi C, Kositanont U, Chantarojanasiri T,  
254 Suwanjutha S, Kanyok R, Raksakait K, Thongcharoen P. Incidence of *Mycoplasma*  
255 *pneumoniae*, *Chlamydia trachomatis*, and viral infections in pneumonia cases under six  
256 months of age, Bangkok, Thailand. Southeast Asian J. Trop. Med. Public Health 1994.  
257 25:657-663.
- 258 16. Marston B J, Plouffe J F, File T M, Jr, Hackman B A, Salstrom S J, Lipman H B, Kolczak  
259 M S, Breiman R F. Incidence of community-acquired pneumonia requiring  
260 hospitalization. Results of a population-based active surveillance Study in Ohio. The

- Community-Based Pneumonia Incidence Study Group. Arch. Intern. Med 1997. 157: 1709-1718.
17. Al-Ghizawi G J, Al-Sulami A A, Al-Taher S S. Profile of community- and hospital-acquired pneumonia cases admitted to Basra General Hospital, Iraq. East Mediterr Health J 2007. 13:230-242.
18. Salama O E. A study of nosocomial infection in a general hospital. J Egypt. Public Health Assoc 1996. 71: 31-46.
19. Pietrzyk A, Wojkowska-Mach J, Bulanda M, Heczko P B. Hospital acquired pneumonia--analysis of frequency and etiology in Polish hospitals in 1998. Przegl. Epidemiol 2000. 54: 259-269.
20. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is *Streptococcus pneumoniae* the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am. J. Med 1999. 106: 385-390.
21. El-Sheikh S M, El-Assouli S M, Mohammed K A, Albar M. Bacteria and viruses that cause respiratory tract infections during the pilgrimage (Haj) season in Makkah, Saudi Arabia. Trop. Med. Int. Health 1998. 3: 205-209.
22. Wright GD. Bacterial resistance to antibiotics: Enzymatic degradation and modification. Adv. Drug Deliv. Rev. 2005; 57:1451–1470.
23. Lambert PA. Bacterial resistance to antibiotics: Modified target sites. Adv. Drug Deliv. Rev. 2005;57:1471-1485.
24. Kumar A, Schweizer HP. Bacterial resistance to antibiotics: Active efflux and reduced uptake. Adv. Drug Deliv. Rev.2005;57:1486-1513.
25. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist. Updates. 1999; 2:38-55




Fig 3.1 Frequency (%) of gram +ve and gram -ve etiological agents




Fig 3.2 Distribution of etiological agents among hospitals wards




**Fig 3.3 Antibiotics resistance (%) on different etiological agents causing pneumoniae**

Table 3.1 Resistance rates among Gram-positive clinical isolates.

| Organism                        | Isolates identified | Ampicillin | Amikacin | Augmentin | Ampicillin/sulbactam | Cefazolin | Cefotaxime | Ceftriaxone | Clindamycin | Ciprofloxacin | Erythromycin | Gentamicin | Imipenem | Levofloxacin | Linezolid | Norfloxacin | Oxacillin | Penicillin-G | Rifampin | Tetracycline | Trimethoprim/sulfa | Vancomycin |
|---------------------------------|---------------------|------------|----------|-----------|----------------------|-----------|------------|-------------|-------------|---------------|--------------|------------|----------|--------------|-----------|-------------|-----------|--------------|----------|--------------|--------------------|------------|
| <i>Staphylococcus aureus</i>    | %                   | 94.7       | 67.3     | 73.5      | 73.9                 | 52.2      | 58.6       | 71.1        | 57.7        | 57.1          | 60.8         | 54.1       | 61.4     | 43.3         | 24.4      | 75          | 65.2      | 94.7         | 30.1     | 55           | 38.5               | 0          |
|                                 | 241                 | 189        | 101      | 166       | 69                   | 23        | 87         | 149         | 215         | 184           | 217          | 196        | 57       | 30           | 78        | 4           | 221       | 171          | 83       | 160          | 226                | 203        |
| <i>Streptococcus pneumoniae</i> | %                   | 10.5       | 80       | 7.1       | 0                    |           | 15.4       | 10          | 14.3        | 30            | 10.5         | 66.7       | 10.0     |              | 0         |             | 0         | 15           | 33.3     | 70           | 73.7               | 0          |
|                                 | 23                  | 19         | 5        | 14        | 2                    |           | 13         | 10          | 21          | 10            | 19           | 9          | 10       |              | 7         |             | 6         | 20           | 3        | 10           | 19                 | 13         |
| <i>Enterococcus faecalis</i>    | %                   | 0          | 100      | 50        |                      |           | 100        | 100         | 100         | 62.5          | 83.3         | 100        | 100      |              | 20        |             | 100       | 50           | 100      | 71.4         | 50                 | 0          |
|                                 | 9                   | 9          | 1        | 2         |                      |           | 2          | 1           | 3           | 8             | 6            | 7          | 1        |              | 5         |             | 1         | 2            | 1        | 7            | 2                  | 9          |

Each organism is presented in two rows. The top row represents its resistance in percent to that antibiotic. The 2nd row represents number of isolates tested for that specific antibiotic. Resistance equal to 100% is highlighted in (Aqua color), and equal to 0% in (Purple color). The empty shaded cells (red color) indicate that susceptibility testing for that specific organism is not recommended or complete testing data was not available. Odd rows express values as %age while even rows value expressed total number.

321 Table 3.2 Resistance rates among Gram-negative clinical isolates.

| Organism                       | Isolates identified |   | Ampicillin | Amikacin | Augmentin | Ampicillin/sulbactam | Aztreonam | Cefepime | Cefazolin | Cefuroxime | Cefotaxime | Cefoxitin | Ceftazidime | Ceftriaxone | Cephalothin | Ciprofloxacin | Gentamicin | Imipenem | Levofloxacin | Nitrofurantoin | Piperacillin | Piperacillin-tazobactam | Tetracycline | Ticarcillin/clavulanate | Tobramycin | Trimethoprim/sulfa |
|--------------------------------|---------------------|---|------------|----------|-----------|----------------------|-----------|----------|-----------|------------|------------|-----------|-------------|-------------|-------------|---------------|------------|----------|--------------|----------------|--------------|-------------------------|--------------|-------------------------|------------|--------------------|
| <i>Acinetobacter baumannii</i> | 270                 | % | 96.6       | 85.2     | 97.3      | 77.6                 | 93.4      | 93.8     | 93.1      | 91.5       | 94.7       | 97.1      | 91.6        | 94.3        | 96.9        | 94.2          | 80.9       | 70.5     | 82.1         | 92             | 94.7         | 92.4                    | 79.7         | 91.7                    | 64.6       | 88.1               |
|                                |                     |   | 177        | 250      | 150       | 107                  | 181       | 225      | 58        | 118        | 226        | 170       | 251         | 123         | 162         | 241           | 241        | 234      | 95           | 50             | 247          | 158                     | 212          | 84                      | 113        | 236                |
| <i>Pseudomonas aeruginosa</i>  | 371                 | % | 67         | 38.2     | 65.3      | 38.5                 | 49.7      | 47.2     | 39.5      | 65.8       | 74.2       | 68.5      | 49.2        | 68          | 68.1        | 43.3          | 47         | 29.2     | 51.6         | 36.6           | 51.7         | 36.7                    | 76.7         | 50                      | 40.5       | 68.6               |
|                                |                     |   | 88         | 343      | 75        | 39                   | 147       | 318      | 43        | 73         | 168        | 89        | 307         | 128         | 91          | 312           | 332        | 319      | 95           | 41             | 300          | 245                     | 73           | 102                     | 131        | 105                |
| <i>Klebsiella pneumoniae</i>   | 238                 | % | 94.3       | 23.4     | 54.3      | 64.6                 | 63.9      | 57.5     | 70        | 64.5       | 59.2       | 45.6      | 58.3        | 59.8        | 72.9        | 56.3          | 50.5       | 13.1     | 55.2         | 64.1           | 74.9         | 38.3                    | 62.2         | 48.3                    | 62.8       | 57.4               |
|                                |                     |   | 212        | 222      | 175       | 65                   | 122       | 200      | 60        | 169        | 174        | 160       | 192         | 102         | 207         | 208           | 218        | 199      | 58           | 39             | 175          | 175                     | 143          | 58                      | 78         | 209                |
| <i>Klebsiella oxytoca</i>      | 11                  | % | 77.8       | 0        | 60        | 50                   | 83.3      | 33.3     | 100       | 42.9       | 37.5       | 66.7      | 44.4        | 66.7        | 87.5        | 37.5          | 12.5       | 11.1     | 50           | 50             | 75           | 11.1                    | 42.9         | 50                      | 100        | 50                 |
|                                |                     |   | 9          | 8        | 5         | 2                    | 6         | 9        | 2         | 7          | 8          | 6         | 9           | 3           | 8           | 8             | 8          | 9        | 2            | 2              | 8            | 9                       | 7            | 2                       | 2          | 8                  |
| <i>Escherichia coli</i>        | 94                  | % | 96.4       | 22.2     | 73.7      | 85.7                 | 72.3      | 68.5     | 85.7      | 81.1       | 71.4       | 42.9      | 68.6        | 65.2        | 91.7        | 70            | 63.6       | 8        | 100          | 60             | 88.2         | 39.3                    | 80           | 44.4                    | 90.9       | 78.5               |
|                                |                     |   | 84         | 90       | 76        | 7                    | 65        | 73       | 7         | 53         | 70         | 77        | 86          | 23          | 84          | 80            | 88         | 87       | 6            | 10             | 76           | 61                      | 50           | 9                       | 11         | 79                 |
| <i>Proteus mirabilis</i>       | 93                  | % | 96.1       | 77       | 79.2      | 75                   | 48.5      | 59.1     | 83.3      | 87.5       | 76.6       | 75.7      | 72          | 63          | 89.2        | 84.6          | 91.7       | 20       | 81.8         | 81.8           | 93.3         | 36.1                    | 100          | 15.4                    | 73.3       | 93.1               |
|                                |                     |   | 77         | 87       | 77        | 12                   | 68        | 88       | 12        | 56         | 77         | 74        | 82          | 27          | 83          | 78            | 84         | 85       | 11           | 11             | 75           | 72                      | 53           | 22                      | 15         | 87                 |
| <i>Enterobacter cloacae</i>    | 18                  | % | 93.3       | 23.5     | 91.7      | 80                   | 72.7      | 40       | 100       | 87.5       | 80         | 100       | 76.5        | 75          | 100         | 17.6          | 41.2       | 11.8     | 40           | 100            | 86.7         | 60                      | 50           | 80                      | 50         | 43.8               |
|                                |                     |   | 15         | 17       | 12        | 5                    | 11        | 15       | 5         | 16         | 15         | 11        | 17          | 8           | 17          | 17            | 17         | 17       | 5            | 1              | 15           | 15                      | 12           | 5                       | 6          | 16                 |
| <i>Enterobacter aerogenes</i>  | 10                  | % | 90         | 60       | 100       | 75                   | 50        | 70       | 100       | 71.4       | 71.4       | 60        | 77.8        | 83.3        | 88.9        | 66.7          | 60.0       | 22.2     | 40           | 100            | 87.5         | 22.2                    | 85.7         | 75%                     | 83.3       | 80                 |
|                                |                     |   | 10         | 10       | 5         | 4                    | 4         | 10       | 4         | 7          | 7          | 5         | 9           | 6           | 9           | 9             | 10         | 9        | 5            | 2              | 8            | 9                       | 7            | 4                       | 6          | 10                 |
| <i>Haemophilus influenzae</i>  | 12                  | % | 36.4       | 14.3     | 10        |                      | 40        | 25       | 0         | 0          | 14.3       | 12.5      | 20          | 0           | 45.5        | 25            | 16.7       | 16.7     |              |                | 75           | 100                     | 66.7         |                         |            | 90.9               |
|                                |                     |   | 11         | 7        | 10        |                      | 5         | 4        | 1         | 5          | 7          | 8         | 5           | 1           | 11          | 8             | 6          | 6        |              |                | 4            | 1                       | 3            |                         |            | 11                 |
| <i>Serratia marcescens</i>     | 29                  | % | 96.4       | 25       | 100       | 83.3                 | 53.3      | 48.1     | 90.9      | 95.7       | 60         | 77.8      | 50          | 60          | 96.2        | 42.3          | 42.9       | 19.2     | 58.3         | 75             | 65.2         | 38.1                    | 68.2         | 40                      | 61.5       | 44.8               |
|                                |                     |   | 28         | 28       | 19        | 12                   | 15        | 27       | 11        | 23         | 25         | 18        | 28          | 15          | 26          | 26            | 28         | 26       | 12           | 4              | 23           | 21                      | 22           | 10                      | 13         | 29                 |
| <i>Providencia stuartii</i>    | 29                  | % | 96.6       | 70.4     | 100       | 85                   | 66.7      | 74.1     | 100       | 88.5       | 76         | 42.9      | 75          | 76.2        | 100         | 85.7          | 92.9       | 14.8     | 68.4         | 100            | 44.4         | 23.1                    | 100          | 15.8                    | 95.2       | 82.6               |
|                                |                     |   | 29         | 27       | 7         | 20                   | 6         | 27       | 20        | 26         | 25         | 7         | 28          | 21          | 27          | 28            | 28         | 27       | 19           | 2              | 27           | 26                      | 26           | 19                      | 21         | 23                 |
| <i>Citrobacter Species</i>     | 8                   | % | 62.5       | 50       | 100       | 100                  | 66.6      | 50       | 100       | 100        | 50         | 100       | 50          | 100         | 83.3        | 100           | 25         | 25       | 100          | 100            | 100          | 50                      | 100          | 0                       | 100        | 83.3               |
|                                |                     |   | 5          | 2        | 2         | 1                    | 3         | 2        | 1         | 2          | 2          | 2         | 4           | 1           | 6           | 4             | 2          | 4        | 1            | 1              | 4            | 2                       | 2            | 1                       | 1          | 6                  |

|                                     |    |   |     |      |     |      |     |      |     |     |     |      |      |     |     |      |     |      |      |     |      |      |      |      |      |      |
|-------------------------------------|----|---|-----|------|-----|------|-----|------|-----|-----|-----|------|------|-----|-----|------|-----|------|------|-----|------|------|------|------|------|------|
| <i>Morganella morganii</i>          | 12 | % | 100 | 58.3 | 100 | 57.1 | 100 | 36.4 | 100 | 75  | 40  | 50   | 45.5 | 40  | 100 | 58.3 | 90  | 12.5 | 57.1 | 100 | 63.6 | 18.2 | 100  | 28.6 | 88.9 | 91.7 |
|                                     |    |   | 12  | 12   | 6   | 7    | 1   | 11   | 7   | 8   | 10  | 2    | 11   | 10  | 11  | 12   | 10  | 8    | 7    | 1   | 11   | 11   | 10   | 7    | 9    | 12   |
| <i>Stenotrophomonas maltophilia</i> | 13 | % | 100 | 100  | 100 | 100  | 100 | 100  | 100 | 100 | 100 | 69.2 | 100  | 100 | 80  | 100  | 100 | 60   | 100  | 80  | 100  | 85.7 | 66.7 | 100  | 8.3  |      |
|                                     |    |   | 8   | 8    | 5   | 2    | 9   | 6    | 2   | 5   | 6   | 6    | 13   | 2   | 8   | 10   | 9   | 10   | 5    | 1   | 10   | 7    | 7    | 3    | 3    | 12   |

322 Each organism is presented in two rows. The top row represents its resistance in percent to that antibiotic. The 2nd row represents number of  
323 isolates tested for that specific antibiotic. Resistance equal to 100% is highlighted in (Aqua color), and equal to 0% in Purple color. The empty  
324 shaded cells (red color) indicate that susceptibility testing for that specific organism is not recommended or complete testing data was not  
325 available. Odd rows express values as %age while even rows value expressed total number